Leiper James M
Centre for Clinical Pharmacology, British Heart Foundation Laboratories, Division of Medicine, University College London, UK.
Ther Drug Monit. 2005 Dec;27(6):744-6. doi: 10.1097/01.ftd.0000179849.42395.11.
An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS),particularly asymmetric dimethylarginine (ADMA), regulate nitric oxide generation in disease states. This article describes the biology of ADMA and the implications for cardiovascular physiology and pathophysiology.
文献中越来越多的报告表明,内源性一氧化氮合酶(NOS)抑制剂,尤其是不对称二甲基精氨酸(ADMA),在疾病状态下调节一氧化氮的生成。本文描述了ADMA的生物学特性及其对心血管生理和病理生理的影响。